Home » Topics » Regulatory » EMA

EMA
RSS

EMA confirms that MAA for AcelRx's sublingual sufentanil can use centralized procedure

Dec. 24, 2015

EMA accepts Vanda's MAA for Fanaptum

Dec. 23, 2015

EMA CHMP recommends approval of Sanofi Pasteur MSD's hexavalent vaccine Vaxelis

Dec. 22, 2015

EMA committee supports approval of Shield's Feraccru to treat iron deficiency anemia

Dec. 22, 2015

CHMP recommends approval of Lilly's necitumumab and ramucirumab

Dec. 22, 2015

EMA committee backs approval of Brilique 60 mg for patients with history of heart attack

Dec. 21, 2015

EMA CHMP recommends approval of AstraZeneca's osimertinib for NSCLC

Dec. 21, 2015

Bayer's recombinant factor VIII BAY-81-8973 receives positive CHMP opinion

Dec. 21, 2015

EMA committee recommends approval of lesinurad for hyperuricemia in gout

Dec. 21, 2015

Committee backs E.U. orphan drug designation for axalimogene filolisbac in anal cancer

Dec. 16, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.